Phenylacetylglutamine (PG or PAG)

Dvorit D. SAMID learned about PHENYLACETYLGLUTAMINATE (PG or PAG) from Burzynski
� � � � � � � � � � � � � � � � �
PHENYLACETYLGLUTAMINATE (PG or PAG) and Phenylacetate (PN) are metabolites of Phenylbutyrate (PB) and are constituents of antineoplaston AS2-1
� � � � � � � � � � � � � � � � �
Antineoplastons AS2-1 and AS2-5 are DERIVED FROM A10
� � � � � � � � � � � � � � � � �
AS2-1=4:1 mixture of Phenylacetic Acid (PA) and PHENYLACETYLGLUTAMINE (PAG or PG)
� � � � � � � � � � � � � � � � �
Antineoplaston AS2-5 = PHENYLACETYLGLUTAMINE (PAG or PG)
� � � � � � � � � � � � � � � � �
National Cancer Institute (NCI)
at the National Institutes of Health (NIH) Antineoplastons
General Information:
http://www.cancer.gov/cancertopics/pdq/cam/antineoplastons/healthprofessional/page2
� � � � � � � � � � � � � � � � �
4/1994 A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer
SAMID D
phase I…study of intravenous Phenylacetate=PN in patients with cancer
http://www.ncbi.nlm.nih.gov/pubmed/8137283
Cancer Res. 1994 Apr 1;54(7):1690-4
http://www.ncbi.nlm.nih.gov/m/pubmed/8137283
Cancer Res April 1, 1994 54; 1690
http://m.cancerres.aacrjournals.org/content/54/7/1690.full.pd
Cancer Res 1994;54:1690-1694
http://m.cancerres.aacrjournals.org/content/54/7/1690.abstract
Clinical Pharmacology Branch, National Cancer Institute, NIH, Bethesda, Maryland
http://cancerres.aacrjournals.org/content/54/7/1690
PN (Phenylacetate) elimination was accounted for by conversion to PHENYLACETYLGLUTAMINATE (PG or PAG) … excreted in the urine
http://m.cancerres.aacrjournals.org/content/54/7/1690.full.pdf
A A Thibault, …, D D SAMID et al.
Cancer Res 54(7):1690-4 (1994), PMID.8137283
Burzynski Reference: 13
� � � � � � � � � � � � � � � � �
4/1995 Disposition of phenylbutyrate and its metabolites, phenylacetate and PHENYLACETYLGLUTAMINATE
SAMID D et al
Disposition of PB and its metabolites PN and PG (PAG)
Burzynski
http://www.ncbi.nlm.nih.gov/pubmed/7650225
J Clin Pharmacol. 1995 Apr;35(4):368-73
http://www.ncbi.nlm.nih.gov/m/pubmed/7650225
J Clin Pharmacol 35(4):368-73 (1995), PMID.7650225
http://onlinelibrary.wiley.com/doi/10.1002/j.1552-4604.1995.tb04075.x/abstract;jsessionid=314D898507527C2793B578096D7E3C0F.d01t03
Article first published online: 8 MAR 2013
DOI: 10.1002/j.1552-4604.1995.tb04075.x
Pharmacy Department, National Institutes of Health, Bethesda, Maryland, USA
Dvorit SAMID … A A Thibault, … et al.

A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer
http://www.ncbi.nlm.nih.gov/m/pubmed/8137283
A A Thibault, …, D D SAMID et al.
Cancer Res 54(7):1690-4 (1994), PMID.8137283
Cancer Res. 1994 Apr 1;54(7):1690-4
Clinical Pharmacology Branch, National Cancer Institute, NIH, Bethesda, Maryland
phenylacetate elimination was accounted for by conversion to phenylacetylglutamine, which was excreted in the urine
http://cancerres.aacrjournals.org/content/54/7/1690
References: 8 – 13

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s